News | December 11, 2025
Bristol Myers Squibb unveils breakthrough Lymphoma data
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
Captured microbes are then neutralized on engineered microbicidal surfaces
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Valorum will advance the commercialization and distribution of Armlupeg in the United States
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Subscribe To Our Newsletter & Stay Updated
